---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028343"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:23:26.796729+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint

## Summary
- Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.
- Net loss of $47.6M in Q4 2024 (vs $23.8M Q4 2023); FY 2024 net loss $167.4M (vs $153.2M).
- R&D expenses $40.5M Q4 2024 (vs $34.8M); G&A $14.6M (vs $10.6M) year-over-year.
- Zipalertinib Phase 2b met primary endpoint (ORR); full results mid-2025; NDA submission planned H2 2025.
- Initial CLN-978 SLE data expected Q4 2025; CLN-619 endometrial/cervical cancer data expected Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-028343
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/0000950170-25-028343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028343
- JSON: https://secwatch.observer/filing/0000950170-25-028343.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.